Inhibition of BCL-XL has been identified as a potent senolytic strategy, and thus treatment with A1331852 may have the additional benefit of targeting senescent cells.41,42 Taken together, these findings underscore the importance of BCL-XL as therapeutic target in neuroblastoma. Here, BCL2L1 is linked to neuroblastoma.